SENOVAC
| 神诺威
中文 / EN
SENOVAC
| 神诺威
Pioneering Immuno-senolytic Therapies. Developing vaccines and antibody drugs for age-related diseases like fibrosis and metabolic syndrome.
免疫抗衰疗法的先行者。针对老龄相关疾病（如纤维化和代谢综合征）开发突破性的疫苗及抗体药物。
Our Science 探索我们的科学Targeting the root cause of aging to extend healthy lifespan.
直击衰老根源，延长人类健康寿命。
Aging is the biggest risk factor for chronic diseases. Current solutions lack tissue specificity or have high toxicity. China alone will have 400 million people over 60 by 2035.
衰老是慢性疾病最大的风险因子。现有的抗衰手段往往缺乏组织特异性或存在毒性风险。面对老龄化社会的万亿级需求，我们需要更安全有效的方案。
We benchmark tumor immunotherapy principles to clear senescent cells. Our goal: Rejuvenate, Prevent Chronic Diseases, Extend Healthspan, & Delay Ageing.
我们对标肿瘤免疫疗法，利用免疫系统精准清除衰老细胞。目标：防治老年慢性病、延长健康寿命、延缓衰老、重焕青春活力。
Integrated immune-based strategy supported by >25 years of research and AI innovation.
基于超过25年科研积累与AI赋能的综合免疫抗衰策略。
Activating immune recognition to specifically clear senescent cells, reducing SASP and promoting regeneration.
激活免疫系统特异清除衰老细胞，降低SASP，促进再生。
Peptide drugAntibodies>100 targets screened; >10 validated novel seno-antigens with high tissue specificity.
筛选100+靶点，验证10+具高组织特异性的衰老抗原。
Multi-omicsSpecific AntigensDeep learning for target mining; generative AI to optimize Bispecific/TCE and ADC structures.
深度学习挖掘靶点；生成式AI优化双抗/TCE与ADC分子。
Generative DesignStructural OptimizationHarness immune recognition to selectively eliminate senescent cells and reduce SASP-driven inflammation, enabling tissue repair and functional recovery.
利用免疫识别选择性清除衰老细胞，降低SASP炎症因子负担，从而促进组织修复与功能恢复。
We integrate multi-omics, single-cell profiling and functional validation to identify tissue-selective seno-antigens suitable for drug development.
整合多组学、单细胞与功能验证，系统发现具组织选择性的衰老抗原，为药物开发提供可转化靶点。
Deep learning accelerates target mining and triage; generative AI supports rapid optimization of bispecific/TCE and ADC designs.
深度学习加速靶点挖掘与优先级排序；生成式AI支持双抗/TCE与ADC的快速优化迭代。
| Program 项目名称 | Indication 适应症 | Modality 药物形式 | Development Stage 研发阶段 |
|---|---|---|---|
| HDT011 | Obesity & Metabolic Syndrome 肥胖与代谢综合征 | Peptide drug / Antibody 多肽药物 / 抗体 | Pre-clinical / IIT Prep 临床前 / IIT准备 |
| HDT012 | Pulmonary Fibrosis (IPF) 特发性肺纤维化 (IPF) | Bispecific Antibody 双特异性抗体 | Lead Optimization 先导化合物优化 |
| Pet-Seno | Pet Anti-aging 宠物抗衰老 | Vaccine 疫苗 | IND Enabling IND 申报准备 |
| Sen-ADC | Aging-related diseases / Organ premature aging 衰老相关疾病 / 器官早衰 | ADC 抗体偶联药物 | Discovery 发现阶段 |
World-renowned scholars and industry experts.
由国际知名学者与资深产业专家领衔。
Founder Scientist
创始科学家
HKU Professor, 30+ years in aging research.
香港大学教授，30+年衰老研究经验。
Chief Medical Officer
首席医学官
Former Associate Professor, University of Chicago.
前芝加哥大学副教授。
CEO / CFO
首席执行 / 财务官
30 years in capital markets; 15+ years in healthcare investment.
近30年资本市场经验，15+年医疗投资经验。
CTO
首席技术官
HKU PhD; 10+ years in anti-aging R&D.
港大博士，10+年抗衰研发经验。
Flat 1309,13/F King's Commercial Building，NO.2-4 Chatham Court,
100 T.S.T Kln，Hong Kong
香港九龍尖沙咀漆咸圍2–4號
金時商業大廈13樓1309室
Backed by HKU DeepTech100 & ITC TSSSU-O
香港大学 DeepTech100 项目支持
香港创新科技署 TSSSU-O 资助
Source: Company Pitch Deck. (Contact us for details.)
资料来源：公司路演材料（详细信息请联络我们）。
